LTR Pharma Limited (ASX:LTP)

Australia · Delayed Price · Currency is AUD

0.4700

+0.0200 (4.44%)

Nov 11, 2026, 4:10 PM AEDT

Market Cap	85.67M +7.2%
Revenue (ttm)	723.94K -52.0%
Net Income	-14.16M
EPS	-0.08
Shares Out	182.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,862
Open	0.4500
Previous Close	0.4500
Day's Range	0.4350 - 0.4900
52-Week Range	0.3500 - 0.7500
Beta	2.26
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About LTR Pharma

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2020

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol LTP

Full Company Profile

Financial Performance

In fiscal year 2026, LTR Pharma's revenue was 723,935, a decrease of -52.01% compared to the previous year's 1.51 million. Losses were -14.16 million, 153.2% more than in 2025.

Financial Statements